MAPT and Alzheimer disease: Although AD is a progressive neurodegenerative disorder characterized by the “A/T/N” system (i.e., β-amyloid biomarker buildup, tau biomarker buildup, and neurodegeneration or neuronal injury) [2], heterogeneity in disease manifestation and trajectory impact our ability to accurately diagnose or treat AD [3,4].